Merck & Co. stock falls 1.45 percent to EUR 129.80 from EUR 131.71

Published on 09/30/2026 at 16:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck & Co. stock was at EUR 129.80 at Lang & Schwarz on September 30, 2026, down 1.45 percent from EUR 131.71. Tulisokibart achieved a 72.00 percent response rate at high dose.

Photorealistic wide-angle view of a modern oncology research laboratory. A scientist in white lab coat examines cancer cell slides under a fluorescence microscope. Amber glass vials with pharmaceutical compounds line the stainless steel bench. Biosafety c — Merck US58933Y1055 Onkologie-Labor: Wissenschaftler am Mikroskop analysiert Krebszellen, mehrere Wirkstoff-Vials stehen auf der Werkbank, Illustration mit AI erstellt.

Merck & Co. stock was trading at EUR 129.80 at Lang & Schwarz on September 30, 2026 at 4:06 p.m. CEST, down 1.45 percent from the prior close of EUR 131.71. The move followed fresh clinical data as Merck reported positive Phase 2b results for tulisokibart in hidradenitis suppurativa.

Tulisokibart clears its main test

The study met its week 16 HiSCR50 primary endpoint in both tested regimens. The high-dose group delivered a 72.00 percent response rate and the medium-dose group reached 64.00 percent, compared with 35.00 percent for placebo, according to Merck's September 30, 2026 release.

The treatment also produced HiSCR75 responses of 41.00 percent at high dose and 40.00 percent at medium dose, versus 15.00 percent for placebo. Adverse events occurred in 42.90 percent of high-dose participants and 47.60 percent of medium-dose participants, compared with 40.90 percent for placebo, keeping safety data central to the next development step.

Q2 revenue beats consensus

Merck's latest reported quarter added a second support point. MarketBeat said Q2 2026 revenue reached USD 16.61 billion, above the USD 16.37 billion consensus estimate. Adjusted EPS was USD -0.13, better than the USD -0.26 consensus, while fiscal 2026 adjusted EPS guidance stood at USD 2.66-2.76.

That comparison matters because the pipeline data arrive alongside an earnings profile that is still rebuilding. The Q2 revenue beat gives the market a measurable operating reference, while tulisokibart offers a potential growth asset beyond Merck's established oncology and vaccine franchises.

Analyst target reaches USD 180

MarketBeat reported on September 29, 2026 that Scotiabank raised its Merck price target from USD 155.00 to USD 180.00 and kept a sector outperform rating. The new target was published against a USD 146.57 reference price in the report, making the target 22.81 percent higher than that reference.

Market capitalization stood at USD 363.5 billion on September 30, 2026. The NYSE quotation ranged from USD 82.01 to USD 156.92 over the prior 52 weeks, placing the US-listed shares below the yearly high while the euro quote remained under pressure.

Merck stock trades at EUR 129.80

Merck & Co. stock was trading at EUR 129.80 at Lang & Schwarz on September 30, 2026 at 4:06 p.m. CEST, down 1.45 percent versus the prior close of EUR 131.71. The company's latest trial result and the raised USD 180.00 analyst target give investors two concrete reference points for assessing the pipeline against near-term earnings volatility.